《美股業績》BioNTech季度獲利和營收超出預期 盤前股價漲逾3%
德國企業BioNTech(BNTX.US)在盤前上漲3.3%,該公司公佈第三季度意外獲利和超出預期的收入,即便受到新冠疫苗收入下降的影響。
該公司第三季度錄淨利潤1.606億歐元,即每股67美仙,按年跌91%,市場原預期錄每股虧損59美仙;收入按年跌97.4%至8.953億歐元,高於市場預期的8.51億歐元。
公司表示,其合作夥伴輝瑞(PFE.US)的庫存減記導致該期間收入減少了5.079億歐元,而COVID-19疫苗收入下降也導致了這一損失。BioNTech目前預計全年新冠疫苗收入總額為40億歐元,低於先前指引的50億歐元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.